Shanghai Hile Bio-tech (603718) - Total Assets
Based on the latest financial reports, Shanghai Hile Bio-tech (603718) holds total assets worth CN¥1.38 Billion CNY (≈ $201.87 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanghai Hile Bio-tech - Total Assets Trend (2011–2025)
This chart illustrates how Shanghai Hile Bio-tech's total assets have evolved over time, based on quarterly financial data. Also see 603718 company net worth for the company's overall valuation and market capitalisation.
Shanghai Hile Bio-tech - Asset Composition Analysis
Current Asset Composition (December 2025)
Shanghai Hile Bio-tech's total assets of CN¥1.38 Billion consist of 53.0% current assets and 47.0% non-current assets. Review Shanghai Hile Bio-tech (603718) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 19.1% |
| Accounts Receivable | CN¥100.85 Million | 9.0% |
| Inventory | CN¥59.46 Million | 5.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥50.70 Million | 4.5% |
| Goodwill | CN¥381.82 Million | 33.9% |
Asset Composition Trend (2011–2025)
This chart illustrates how Shanghai Hile Bio-tech's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 603718 live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Hile Bio-tech's current assets represent 53.0% of total assets in 2025, an increase from 48.6% in 2011.
- Cash Position: Cash and equivalents constituted 19.1% of total assets in 2025, down from 40.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, an increase from 6.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 33.9% of total assets.
Shanghai Hile Bio-tech Competitors by Total Assets
Key competitors of Shanghai Hile Bio-tech based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.40 Billion |
|
ChemPartner PharmaTech Co Ltd
SHE:300149
|
China | CN¥2.04 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Nuvectis Pharma Inc
NASDAQ:NVCT
|
USA | $22.38 Million |
Shanghai Hile Bio-tech - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.65 | 8.62 | 1.30 |
| Quick Ratio | 2.18 | 7.85 | 1.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥373.75 Million | CN¥610.82 Million | CN¥186.21 Million |
Shanghai Hile Bio-tech - Advanced Valuation Insights
This section examines the relationship between Shanghai Hile Bio-tech's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.32 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -38.4% |
| Total Assets | CN¥1.13 Billion |
| Market Capitalization | $291.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Hile Bio-tech's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai Hile Bio-tech's assets decreased by 38.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Hile Bio-tech (2011–2025)
The table below shows the annual total assets of Shanghai Hile Bio-tech from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.13 Billion ≈ $164.64 Million |
-38.41% |
| 2024-12-31 | CN¥1.83 Billion ≈ $267.32 Million |
+10.20% |
| 2023-12-31 | CN¥1.66 Billion ≈ $242.58 Million |
+9.48% |
| 2022-12-31 | CN¥1.51 Billion ≈ $221.58 Million |
-17.89% |
| 2021-12-31 | CN¥1.84 Billion ≈ $269.85 Million |
+3.21% |
| 2020-12-31 | CN¥1.79 Billion ≈ $261.46 Million |
+5.02% |
| 2019-12-31 | CN¥1.70 Billion ≈ $248.95 Million |
-2.70% |
| 2018-12-31 | CN¥1.75 Billion ≈ $255.87 Million |
+9.17% |
| 2017-12-31 | CN¥1.60 Billion ≈ $234.38 Million |
+8.23% |
| 2016-12-31 | CN¥1.48 Billion ≈ $216.56 Million |
+19.32% |
| 2015-12-31 | CN¥1.24 Billion ≈ $181.50 Million |
+89.51% |
| 2014-12-31 | CN¥654.48 Million ≈ $95.77 Million |
+8.93% |
| 2013-12-31 | CN¥600.84 Million ≈ $87.92 Million |
+7.17% |
| 2012-12-31 | CN¥560.66 Million ≈ $82.04 Million |
+11.23% |
| 2011-12-31 | CN¥504.03 Million ≈ $73.76 Million |
-- |
About Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The company offers biochemistry reagents, immunoturbidimetric latex reagents, immune turbidimetry reagents, latex enhanced … Read more